Drug Trial News

RSS

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.

8 May 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

Cell Medica treats first pediatric patient in ASPIRE Trial

Cell Medica today announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of Cytovir ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation.

8 May 2013

Study investigates use of sublingual immunotherapy against ragweed allergy

An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal congestion and itchy eyes experienced by ragweed allergy sufferers.

8 May 2013

Clinical data of cabozantinib to be presented at ASCO meeting

Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.

8 May 2013

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Baxter International Inc. today announced that its Phase III clinical study of immunoglobulin did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

From Baxter International Inc. 8 May 2013

New skin cancer drug successfully tested in humans

A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.

8 May 2013

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC).

7 May 2013

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.

7 May 2013

Study provides additional data on why RV144 vaccine failed to protect more people

Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.

7 May 2013

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

7 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.

3 May 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

3 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

Clinical trial to treat Female Orgasmic Disorder

Columbia University School of Nursing is the only site in New York State, and one of only 30 international sites selected to participate in a clinical trial to treat Acquired Female Orgasmic Disorder.

30 Apr 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

29 Apr 2013

Drug Trial News

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Cell Medica treats first pediatric patient in ASPIRE Trial

Study investigates use of sublingual immunotherapy against ragweed allergy

Clinical data of cabozantinib to be presented at ASCO meeting

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

New skin cancer drug successfully tested in humans

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Study provides additional data on why RV144 vaccine failed to protect more people

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Clinical trial to treat Female Orgasmic Disorder

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News